Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
In a bid to expand its portfolio of immunology products, US biotech Incyte today announced it plans to acquire privately-held Escient Pharmaceuticals. 23 April 2024
Biotechnology
Following an earlier snub, the US Food and Drug Administration has now approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG). 23 April 2024
Biotechnology
French drugmaker Ipsen says it has signed an exclusive worldwide collaboration with privately-held US biotech Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases. 23 April 2024
Pharmaceutical
Swiss pharma giant Novartis today raised its full-year guidance after reporting better-than-expected first-quarter 2024 results, with the firm’s shares rising as much as 4.8% in early trading. 23 April 2024
Biotechnology
A first-in-class treatment for paroxysmal nocturnal hemoglobinuria (PNH), Voydeya (danicopan), has been granted marketing authorization in Europe. 23 April 2024
Pharmaceutical
French drugmaker Sanofi has unveiled positive results from the Phase III LUNA 3 trial of rilzabrutinib. 23 April 2024
Biotechnology
Life under the name Barinthus Biotherapeutics has not started well for the UK company formerly known as Vaccitech. 22 April 2024
Biotechnology
The European Commission (EC) has approved a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel). 22 April 2024
Pharmaceutical
Privately-held Italian drugmaker Chiesi Farmaceutici today announced financial results for full-year 2023. 22 April 2024
Pharmaceutical
Research news featured heavily last week, first with US rare seizures drug developer Marinus Pharmaceuticals presenting disappointing Phase III results for its intravenous (IV) ganaxolone), causing an 80% capitalization hit. Amgen released positive Phase IIa data on its Tezspire in chronic obstructive pulmonary disease (COPD). In a bid to further expand indications for its tirzepatide, Eli Lilly released promising Phase III data for the drug in the treatment of sleep apnea. Also, Vertex Pharmaceuticals updated on its non-opioid pain candidate suzetrigine (VX-548). 21 April 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze